Your browser doesn't support javascript.
loading
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
Vogiatzi, Fotini; Winterberg, Dorothee; Lenk, Lennart; Buchmann, Swantje; Cario, Gunnar; Schrappe, Martin; Peipp, Matthias; Richter-Pechanska, Paulina; Kulozik, Andreas E; Lentes, Jana; Bergmann, Anke K; Valerius, Thomas; Frielitz, Fabian-Simon; Kellner, Christian; Schewe, Denis M.
Affiliation
  • Vogiatzi F; Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Winterberg D; Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Lenk L; Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Buchmann S; Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Cario G; Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Schrappe M; Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Peipp M; Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Richter-Pechanska P; Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg and Hopp Children's Cancer Center at Nationales Centrum für Tumorerkrankungen Heidelberg, Heidelberg, Germany.
  • Kulozik AE; Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg and Hopp Children's Cancer Center at Nationales Centrum für Tumorerkrankungen Heidelberg, Heidelberg, Germany.
  • Lentes J; Institute of Human Genetics, Medical School Hannover, Hannover, Germany.
  • Bergmann AK; Institute of Human Genetics, Medical School Hannover, Hannover, Germany.
  • Valerius T; Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Frielitz FS; Institute of Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany; and.
  • Kellner C; Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, Ludwig Maximilians University Munich, Munich, Germany.
  • Schewe DM; Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Blood ; 134(8): 713-716, 2019 08 22.
Article in En | MEDLINE | ID: mdl-31311816
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasm, Residual / Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Antibodies, Monoclonal / Antineoplastic Agents Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Language: En Journal: Blood Year: 2019 Document type: Article Affiliation country: Germany Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasm, Residual / Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Antibodies, Monoclonal / Antineoplastic Agents Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Language: En Journal: Blood Year: 2019 Document type: Article Affiliation country: Germany Country of publication: United States